【24h】

Protection of Subjects Participating in Clinical Trials

机译:保护受试者参与临床试验

获取原文

摘要

Clinical trials constitute one of the final stages along the testing continuum that is so needed for the introduction of new products, methods, and ground-breaking technologies. Currently, most economies have recognized the importance clinical trials play as part of the entire value chain from idea to product. While most jurisdictions have developed systems of safeguards for the protection of human subjects involved in clinical trials, there are huge disconnects among jurisdictions, institutions and investigators. This article provides some generally accepted international standards and guidelines in relation to subject protection as it pertains to recruitment, confidentiality, monitoring, data storage and data transfer. The need for all trial protocols to be reviewed by a qualified and registered ethics committee, as well as that all legal requirements are met to ensure patient protection, is also highlighted. Since governments and industry see clinical trials as a critical and necessary step in the product development process, there is a need for more translational research, which will increase the demand for more participation in clinical trials. This article will therefore, also address the importance of patient protection if we are to meet these requirements.
机译:临床试验构成了沿着测试连续体的最终阶段之一,这是引入新产品,方法和地面技术的必要条件。目前,大多数经济体都认识到重要的临床试验作为从想法到产品的整个价值链的一部分。虽然大多数司法管辖区都制定了保护临床试验中参与的人类受试者的保障系统,但司法管辖区,机构和调查人员存在巨大的脱节。本文提供了一些普遍接受的国际标准和关于主题保护的指导方针,因为它涉及招聘,机密性,监测,数据存储和数据传输。还突出了所有有资格和注册伦理委员会审查所有试验协议的审查,以及所有法律要求,以确保患者保护。由于政府和行业将临床试验视为产品开发过程中的关键和必要步骤,需要更多的翻译研究,这将增加对更多参与临床试验的需求。因此,本文还将解决患者保护的重要性,如果我们满足这些要求。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号